1-20 of 73
Andrew J Yee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An ATLAS to map MRD with peripheral blood

Clinical Trials & Observations
Andrew J. Yee
Journal: Blood
Blood (2024) 144 (9): 919–920.
https://doi.org/10.1182/blood.2024025189
Published: 2024
Journal Articles

Evaluating Physician-AI Interaction for Multiple Myeloma Management: Paving the Path Towards Precision Oncology

Barbara D Lam, Zeshan Hussain, Fernando A Acosta-Perez, Irbaz Bin Riaz, Maia Jacobs, Andrew J. Yee, David Sontag
Journal: Blood
Blood (2023) 142 (Supplement 1): 2281.
https://doi.org/10.1182/blood-2023-182421
Published: 2023
Journal Articles

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob Laubach, Jacalyn Rosenblatt, Nora Horick, Paul G. Richardson, Noopur Raje, Diana Cirstea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4671.
https://doi.org/10.1182/blood-2023-181019
Published: 2023
Journal Articles

Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide

Diana Cirstea, Rajib Shome, Joseph James Connolly, Emilie Duvallet, Amanda N. R. Joyce, Victor Moyo, Kathleen Lively, Gina Basinsky, Andrew J. Yee, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul G. Richardson, Noopur S. Raje
Journal: Blood
Blood (2023) 142 (Supplement 1): 2017.
https://doi.org/10.1182/blood-2023-189332
Published: 2023
Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Jesus G. Berdeja, David Dingli, Sagar Lonial, Andrew J. Yee, Alfred Chung, Cristina Gasparetto, P. Leif Bergsagel, Vivek Roy, Al-Ola Abdallah, Sharmilan Thanendrarajan, Aimaz Afrough, Laura Rosiñol, Suzanne Trudel, Paula Rodriguez Otero, Cyrille Touzeau, Pierre Bories, Soo Bang, Terry Connolly, Michelle Kim, Chad A. Lewis, Bao-Van Tran Linberg, M. Travis Quigley, Ola Landgren, Saad Z Usmani, Maria-Victoria Mateos, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3391.
https://doi.org/10.1182/blood-2023-174550
Published: 2023
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Noffar Bar, Maria Victoria Mateos, Paz Ribas, Markus Hansson, Laura Paris, Craig C. Hofmeister, Paula Rodriguez Otero, Maria Aranzazu Bermúdez, Thomas Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier De La Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian Kiesel, Jinjie Chen, Alexander Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano Costa
Journal: Blood
Blood (2023) 142 (Supplement 1): 2011.
https://doi.org/10.1182/blood-2023-180013
Published: 2023
Journal Articles

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Narsis Attar, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Matthew J. Frigault, Noopur Raje
Journal: Blood
Blood (2023) 142 (Supplement 1): 6924.
https://doi.org/10.1182/blood-2023-182212
Published: 2023
Journal Articles

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Clinical Trials & Observations
Charlotte E. Graham, Won-Ho Lee, Hadley R. Wiggin, Valentina M. Supper, Mark B. Leick, Filippo Birocchi, Andrew J. Yee, Angelina Petrichenko, John Everett, Frederic D. Bushman, Hossein Sadrzadeh, Otto Rapalino, Daniel Chiu, Isabel Arrillaga-Romany, Marcela V. Maus, Matthew J. Frigault, Kathleen M. E. Gallagher
Journal: Blood
Blood (2023) 142 (14): 1248–1252.
https://doi.org/10.1182/blood.2023021429
Published: 2023
Includes: Supplemental data
Journal Articles

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Clinical Trials & Observations
Philipp Karschnia, Kevin C. Miller, Andrew J. Yee, Kai Rejeski, P. Connor Johnson, Noopur Raje, Matthew J. Frigault, Jorg Dietrich
Journal: Blood
Blood (2023) 142 (14): 1243–1248.
https://doi.org/10.1182/blood.2023020571
Published: 2023
Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C Mo, Omar Nadeem, Andrew J. Yee, Andrew R. Branagan, Jacob Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Jacalyn Rosenblatt, Nora K. Horick, Paul G. Richardson, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 7282–7283.
https://doi.org/10.1182/blood-2022-156328
Published: 2022
Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Hani Hassoun, Susanna J. Jacobus, Paul G. Richardson, Jeffrey A. Zonder, Peter M. Voorhees, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Edward Libby, Brandi Reeves, Michael L. Wang, Larry D. Anderson, Jr., Carter Milner, Cristina J. Gasparetto, Mounzer Agha, Abdullah Khan, David Duane Hurd, David Avigan, Caitlin Costello, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Eva Medvedova, Philip L. McCarthy, Robert Z. Orlowski, Omar Nadeem, Jacob P. Laubach, Marcelo C. Pasquini, Sergio A. Giralt, Kelly Masone, Mehmet K. Samur, Aurore Perrot, Philippe Moreau, Herve Avet-Loiseau, Edie A. Weller, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4834–4838.
https://doi.org/10.1182/blood-2022-162741
Published: 2022
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong, Noffar Bar, Laura Paris, Craig C Hofmeister, Markus Hansson, Armando Santoro, Maria-Victoria Mateos, Paula Rodríguez-Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano J. Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 400–402.
https://doi.org/10.1182/blood-2022-159009
Published: 2022
Journal Articles

Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy

Johannes M. Waldschmidt, Sankalp Arora, Tushara Vijaykumar, Noori Sotudeh, Praveen Anand, Hannah Stuart, Julia Frede, Tim Campbell, Shari M. Kaiser, Manisha Lamba, Nikhil C Munshi, Kenneth C. Anderson, Andrew J. Yee, Birgit Knoechel, Jens G. Lohr, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 9925–9926.
https://doi.org/10.1182/blood-2022-168734
Published: 2022
Journal Articles

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Andrew R. Branagan, Matthew M Lei, Clifton C Mo, Andrew J. Yee, Elizabeth K. O'Donnell, Jorge J. Castillo, Omar Nadeem, Noopur Raje, Steven P Treon, Paul G. Richardson, Rie Nakamoto-Matsubara, Kirsten Meid, Zachary S. Bernstein, Rebecca T. Lyons, Rakesh Verma, Zachary R Hunter, Maria Luisa Guerrera, Catherine A. Flynn, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Nora K. Horick, Shayna Sarosiek
Journal: Blood
Blood (2022) 140 (Supplement 1): 10094–10096.
https://doi.org/10.1182/blood-2022-167899
Published: 2022
Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Cynthia C. Harrington, Jill N. Burke, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri
Journal: Blood
Blood (2021) 138 (Supplement 1): 4082.
https://doi.org/10.1182/blood-2021-146342
Published: 2021
Journal Articles

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

Elizabeth K. O'Donnell, Vera Jean Suman, Susan M. Geyer, Omar Nadeem, Shira Dinner, Andrew J. Yee, Jacob P. Laubach, Clifton C. Mo, Sascha A. Tuchman, Kristen Donadio, Sarah Sinclair, Noopur S. Raje, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 4776.
https://doi.org/10.1182/blood-2021-146274
Published: 2021
Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob P. Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Kerry Spillane, Brenton LaStofka, Jacalyn Rosenblatt, Noopur S. Raje, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 5043.
https://doi.org/10.1182/blood-2021-146284
Published: 2021
Journal Articles

Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma

E. Bridget Kim, Elizabeth O'Donnell, Andrew R. Branagan, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Noopur S. Raje, Andrew J. Yee
Journal: Blood
Blood (2021) 138 (Supplement 1): 5018.
https://doi.org/10.1182/blood-2021-153751
Published: 2021
Journal Articles

Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma

Jessica S. Little, Parth Shah, Adam S. Sperling, Andrew R. Branagan, Omar Nadeem, Andrew J. Yee, Noopur S. Raje, Nikhil C. Munshi, Sarah Hammond
Journal: Blood
Blood (2021) 138 (Supplement 1): 3839.
https://doi.org/10.1182/blood-2021-153942
Published: 2021
Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Jill N. Burke, Cynthia C. Harrington, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri
Journal: Blood
Blood (2021) 138 (Supplement 1): 3044.
https://doi.org/10.1182/blood-2021-146290
Published: 2021